TegoScience's earnings have been declining at an average annual rate of -35.6%, while the Biotechs industry saw earnings growing at 16.4% annually. Revenues have been declining at an average rate of 6.8% per year.
How TegoScience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
KOSDAQ:A191420 Revenue, expenses and earnings (KRW Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
5,827
-8,359
3,033
6,009
31 Dec 25
5,941
-7,012
3,132
5,065
30 Sep 25
6,154
-3,249
3,965
3,801
30 Jun 25
6,516
-1,889
4,191
3,094
31 Mar 25
6,798
3,349
4,412
2,821
31 Dec 24
6,759
3,350
4,466
2,663
30 Sep 24
6,927
3,652
3,732
2,410
30 Jun 24
6,974
3,352
3,613
2,474
31 Mar 24
7,194
-2,659
3,475
2,593
31 Dec 23
7,772
-2,323
3,656
2,576
30 Sep 23
8,016
-1,404
2,113
3,475
30 Jun 23
8,134
-1,301
2,870
2,971
31 Mar 23
8,202
235
3,729
2,027
31 Dec 22
7,678
265
3,534
1,608
30 Sep 22
8,426
1,349
4,854
412
30 Jun 22
8,341
1,254
4,014
1,044
31 Mar 22
8,162
432
3,562
2,062
31 Dec 21
8,300
139
3,906
2,328
30 Sep 21
7,573
-479
4,142
2,421
30 Jun 21
8,235
71
4,089
2,284
31 Mar 21
8,455
993
3,588
1,992
31 Dec 20
8,789
1,831
3,002
1,852
30 Sep 20
8,323
1,761
2,671
1,759
30 Jun 20
7,580
1,338
2,543
1,803
31 Mar 20
6,983
1,273
2,437
1,732
31 Dec 19
6,346
856
2,409
1,700
30 Sep 19
6,723
-2,058
2,612
1,720
30 Jun 19
6,849
-2,142
2,763
1,659
31 Mar 19
7,366
-776
2,939
1,762
31 Dec 18
7,850
-1,826
3,164
1,743
30 Sep 18
8,042
-3,071
3,226
1,762
30 Jun 18
8,245
-2,888
3,350
1,545
31 Mar 18
8,331
-7,515
3,413
1,583
31 Dec 17
8,642
-6,021
3,348
1,568
30 Sep 17
8,568
-2,985
3,182
1,376
30 Jun 17
8,568
-2,610
3,000
1,433
31 Mar 17
8,549
776
2,879
1,415
31 Dec 16
8,343
772
2,857
1,433
30 Sep 16
8,049
1,842
2,907
1,583
30 Jun 16
7,981
1,841
2,845
1,678
31 Dec 15
7,492
1,473
2,925
1,605
Quality Earnings: A191420 is currently unprofitable.
Growing Profit Margin: A191420 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A191420 is unprofitable, and losses have increased over the past 5 years at a rate of 35.6% per year.
Accelerating Growth: Unable to compare A191420's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A191420 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (25.4%).
Return on Equity
High ROE: A191420 has a negative Return on Equity (-17.29%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/01 18:54
End of Day Share Price
2026/06/01 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TegoScience Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.